key: cord-0694240-46nm4tod authors: Vress, D. title: Future vaccinations in pregnancy date: 2021-03-24 journal: Best Pract Res Clin Obstet Gynaecol DOI: 10.1016/j.bpobgyn.2021.03.009 sha: c3af6adb7e47e4bff848a467e41311ffb35c577b doc_id: 694240 cord_uid: 46nm4tod Vaccination in pregnancy provides an important opportunity to target illnesses that are known to impact particularly on pregnant women, fetal development and cause newborn illness. The ability to create antibodies via safe vaccination that cross the placenta can provide protection against maternal, congenital and newborn infection. There are currently multiple vaccines being developed which have direct benefits for pregnant women and their newborns. Group B Streptococcus, Respiratory Syncytial Virus, Cytomegalovirus, Zika, Ebola, Malaria and coronavirus SARS-CoV-2 are all being researched with the view to developing a safe vaccine available for pregnant women. There is also an increased movement towards including pregnant women in vaccine development and trials, challenging the historical, ethical and medicolegal arguments against their involvement in such research. Vaccination in pregnancy provides an important opportunity to target illnesses that are known to impact particularly on pregnant women, fetal development and cause newborn illness. There are currently multiple vaccines being developed which have direct benefits for pregnant women and their newborns. There is also an increased movement towards including pregnant women in vaccine development and trials, challenging the historical, ethical and medicolegal arguments against their involvement in such research. Currently, maternal vaccination to diphtheria, tetanus and pertussis (DTPa) and influenza provide increased maternal antibodies that protect both the mother and baby. These vaccinations cause passive immunity to the fetus and newborn by boosting maternal antibody levels and facilitating the transmission of antibodies across the placenta and through the breast milk. GBS CPS types conjugated to tetanus toxoid (6) . Doing this resulted in increased immunogenicity and resulted in clinical trials in humans. There has been one clinical trial of GBS vaccination in pregnant women using a group B streptococcal type III CPS-tetanus toxoid (GBS III-TT) vaccination. This vaccination was found to be well tolerated, safe and produced antibodies that were functionally active, however the vaccines were type specific and each vaccine was only immunogenic to the particular GBS serotype (5) . Multivalent vaccines against multiple CPS serotypes have been developed and trialled in animal models and healthy, non-pregnant participants (6) . Another protein carrier, a nontoxic variant of the diphtheria toxin isolated from Corynebacterium diphtheriae C7 (β197) cultures, has been shown to be effective in conjugation with GBS capsular polysaccharides. This conjugate was used in a phase 2 trial in African pregnant women with and without HIV infection, between 24 and 25 weeks pregnant, using a trivalent non-adjuvanted CRM197-conjugated GBS vaccine against CPS serotypes Ia, Ib and III. It was found that the vaccine was safe in pregnancy with no serious adverse events, and immunogenicity was achieved, however was less in the HIV affected group (8) . There is ongoing interest in the use of a vaccine against GBS in pregnancy, however progress is slow. The relatively low incidence of neonatal disease means that clinical trials to test vaccine efficacy is difficult. J o u r n a l P r e -p r o o f Respiratory Syncytial Virus (RSV) is an ubiquitous respiratory virus which causes a significant disease burden, with millions of hospitalisations and thousands of deaths in children before 5 years of age each year. In 2015, there were 3.2 million hospitalisations for RSV of which half were for children less than 6 months of age, and 118,000 deaths (10). Infants are particularly susceptible to RSV given their small airways and immature immune systems. RSV infection can also affect pregnant women causing upper and lower respiratory tract infection symptoms. There is limited data on the rates of infection for pregnant patients, however based on influenza studies, RSV may affect 10-13% of pregnancies (11). Given the young age of patients affected by RSV, targeting vaccination in the newborn period or using passive immunity via maternal immunisation is desirable. Furthermore, given that pregnant women may still suffer from infective symptoms of RSV, vaccination in pregnant will confer benefits to the mother too. There is currently no vaccination against RSV in any age group. RSV is an orthopneumovirus that is composed of a non-segmented, single stranded genome that encodes 11 proteins. Of the eight structural proteins produced, three are surface proteins (small hydrophobic (SH), attachment (G) and fusion (F) glycoproteins). The F and G proteins are responsible for the pathogenicity of the virus, with the G protein targeting the ciliated cells of the airway and the F protein allowing viral penetrance into causing cell fusion. Protein F is the ideal target for vaccination as it carries several antigenic sites for antibodies to neutralise its function (12) . The history of vaccination development against RSV is rocky. The first vaccine was produced in the 1960's as a formalin-inactivated RSV vaccination and was found to initially J o u r n a l P r e -p r o o f be well tolerated however ultimately resulting in more serious infections in naïve infants with an 80% hospitalisation rate and 2 deaths (13) . Since then, multiple vaccines have been developed including live-attenuated, chimeric, particle-based, vector-based and subunit vaccines (14) . There are currently several vaccines in clinical development for maternal vaccination. Currently the most advanced vaccine in clinical development is the particle-based vaccination against protein F. Live and live-attenuated vaccinations are also being developed for paediatric and elderly populations but are not suitable for maternal vaccination given their live status and risk of maternal infection. A recombinant, adjuvant RSV nanoparticle vaccine (RSV F vaccine) has been studied in pregnant women in the PREPARE trial. The phase 2 trial in 50 women was promising, showing significantly increased antibody production against RSV epitopes in the vaccinated group with evidence of transplacental antibody transfer in the vaccinated group, particularly those who delivered more than 30 days after vaccination, resulting in no severe RSV disease in the infants of vaccinated mothers (15) . The phase three trial evaluated the use of RSV F vaccine amongst 4636 pregnant women in the third trimester in a randomised, observer-blind, placebo-controlled trial across 87 sites in 11 different countries. The percentage of infants who had RSV-associated significant lower respiratory tract infection through 90 days was 1.5% in the vaccine group and 2.4% in the placebo group, giving an estimated vaccine efficacy of 39.4% (10). Overall the vaccination was found to be safe with no major side effects however the study did not meet the success criterion to define an effective vaccination against RSV-associated illness. The search for a successful RSV vaccination is still ongoing. RSV F protein vaccination in pregnant women has not met the prespecified success criterion for efficacy against RSVassociated, medically significant lower respiratory tract infection in infants up to 90 days of life however subanalyses and further studies may show other benefits without harm. Cytomegalovirus (CMV) is the most common congenitally transmitted pathogen worldwide. It is commonly transmitted via close contacts in households with relatively high rates of reinfection or reactivation. CMV congenital infection impacts 1 in 150 live born infants globally, making it a major cause of congenital abnormalities and a suitable target for vaccination (16) . Congenital CMV infection is a well-recognised and important cause of sensorineural hearing loss, growth restriction, cognitive and motor impairment in newborns (17) . Vertical transmission occurs during primary or reinfection with CMV during pregnancy, causing viral infection in the cytotrophoblasts in the placenta (16) . It has been found that there are lower congenital infections in women reinfected with CMV compared to primary infections as well as the severity of congenital infection reduced in seropositive mothers (18) . A maternal vaccination to prevent CMV, particularly primary infection, would have benefits for both mother and child. Attempts to produce such a vaccine has been occurring for over 40 years with the target population of childbearing females prioritised (16) . In the 1970's, two attenuated viral vaccines were developed against CMV. The AD169 attenuated strain was quickly abandoned in the laboratory whilst the 'Towne' vaccination went on to have testing in male and female volunteers. This vaccine showed a nonstatistically significant immunogenic response, and no protection to women who were exposed to CMV by children in day care (18) . In the 1990's, a vaccine against the CMV surface protein glycoprotein B with the adjuvant MF59 (a squalene-in-water emulsion) was developed and entered in to clinical trials (18) . This was found to be both safe and immunogenic over three injections in a 6-month period. Multiple other vaccines have been attempted with ongoing research occurring. Enveloped virus-like particle vaccines use protein structures that mimic viruses, however do not contain any live viral or viral genomic material, to create an immune response. This technology has been used to create vaccines that express CMV glycoprotein B and pp65 antigens and has only recently undergone phase 1 testing (19) . These forms of vaccines may form a safe approach to vaccination in pregnancy if shown to be effective. Other vaccines include J o u r n a l P r e -p r o o f vectored CMV vaccines using attenuated canarypox or Venezuelan equine encephalitis vaccine (19) . Canarypox vectored vaccines have failed to produce an increased neutralising antigen titre on its own, nor any advantage over natural CMV infection when combined with live attenuated vaccines such as the Towne vaccine (21) . Preclinical work has begun on DNA and RNA based vaccines with positive results in animal studies, however their potential use in pregnant women is unclear (19) . vivax in South East Asia. The complexity of the genetic makeup of the parasites is also contributing to the delay in vaccination production, with the P. falciparum genome made of 5300 genes alone with demonstrable geographic diversity (28) . Currently there is one vaccine being implemented against Malaria in Africa against Plasmodium falciparum. The vaccine, RTS,S/AS01 (known as Mosquirix), is the first vaccine to show partial immunity in young children. It was first created in 1987, resulting in a recombinant protein-based malaria vaccine that provides an immune response against the circumsporozoite protein, targeting the sporozoite phase of the lifecycle, preventing the parasite from entering the liver (29) . The phase 3 trial ended in 2014 and the current implementation program will also form the basis for phase 4 studies. The vaccination is not Malaria vaccine trials in pregnant women: An imperative without precedent A Maternal vaccine against group B Streptococcus: past, present, and future. Vaccine Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine Group B Streptococcus vaccine: state of the art. Therapeutic Advances in Vaccines Correlation of Maternal Antibody Deficiency with Susceptibility to Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial Group B streptococcus vaccines: one step further The journey to a respiratory syncytial virus vaccine Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population Respiratory syncytial virus (RSV): a scourge from infancy to old age Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines to Reduce Congenital Cytomegalovirus Infections Vaccine Prevention of Maternal Cytomegalovirus Infection Vaccination against the human cytomegalovirus Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) Zika virus vaccine development: Progress in the face of new challenges Zika Vaccine Development -Current Progress and Challenges for the Future In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunization with a prMEnv DNA vaccine Maternal vaccination and protective immunity against Zika virus vertical transmission Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. The Lancet -Child and Adolescent Health Diversify and Conquer: The Vaccine Escapism of Plasmodium falciparum. Microorganisms Mosquirix TM ): an overview The history of the RTS,S/AS01 malaria vaccine trial Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria Ebola vaccine trials: progress in vaccine safety and immunogenicity Pregnancy and breastfeeding in the context of Ebola: a systematic review Inactivated vaccine for Ebola virus efficacious in guinea pig model Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebocontrolled, phase 2 trial The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak Benefits risk analysis of vaccination of pregnant women with rVSV-ZEBOV as part of expanded access programme. London School of Hygiene & Tropical Medicine World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard A Review of the Progress and Challenges of Developing a Vaccine for COVID-19 SARs-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes Oxford-AstraZeneca COVID-19 vaccine efficacy Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine COVID-19 vaccines and neglected pregnancy Royal college of Obstetricians & Gynaecologists. Coronavirus (COVID-19) Infection in Pregnancy. Version 12 Ethical Considerations for Including Women as Research Participants. ACOG Committee Opinion Number 646 The challenges of pregnancy in clinical trials for vaccines